Global Information
회사소개 | 문의

GTPase KRas : 파이프라인 리뷰

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H1 2018

리서치사 Global Markets Direct
발행일 2018년 05월 상품 코드 371942
페이지 정보 영문 70 Pages
가격
US $ 3,500 ₩ 4,001,900 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 8,003,800 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 12,005,700 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


GTPase KRas : 파이프라인 리뷰 GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H1 2018
발행일 : 2018년 05월 페이지 정보 : 영문 70 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

GTPase KRas를 표적으로 한 치료제 개발 파이프라인의 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업 및 연구기관에 의해 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트에 관한 정보 등을 최신 뉴스 및 발표와 함께 정리하여 전해드립니다.

서론

  • 조사 범위

GTPase KRas 개요

치료제 개발

  • 개발중인 제품 : 개발 단계별
  • 개발중인 제품 : 치료 영역별
  • 개발중인 제품 : 증상별

파이프라인 제품의 상황 개요

  • 초기 단계 제품

기업에서 개발중인 제품

대학/기관에서 개발중인 제품

치료제 평가

  • 단일요법/병용 치료제의 경우
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

치료제 개발에 참여하고 있는 기업

  • Aurigene Discovery Technologies Limited
  • Boehringer Ingelheim GmbH
  • Horizon Discovery Group Plc
  • Nimbus Therapeutics, LLC
  • Nuevolution AB
  • PeptiDream Inc.
  • Tosk, Inc.
  • Warp Drive Bio, Inc.

약제 개요

휴지중인 프로젝트

주요 뉴스 및 프레스 릴리스

부록

도표

KSA 16.10.11

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indication, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Number of Products under Investigation by Universities/Institutes, H1 2018
  • Products under Investigation by Universities/Institutes, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by AstraZeneca Plc, H1 2018
  • Pipeline by Aurigene Discovery Technologies Ltd, H1 2018
  • Pipeline by Boehringer Ingelheim GmbH, H1 2018
  • Pipeline by Codiak BioSciences Inc, H1 2018
  • Pipeline by Cotinga Pharmaceuticals Inc, H1 2018
  • Pipeline by InteRNA Technologies BV, H1 2018
  • Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018
  • Pipeline by Mirati Therapeutics Inc, H1 2018
  • Pipeline by Moderna Therapeutics Inc, H1 2018
  • Pipeline by Nuevolution AB, H1 2018
  • Pipeline by PeptiDream Inc, H1 2018
  • Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
  • Pipeline by Tosk Inc, H1 2018
  • Pipeline by Warp Drive Bio Inc, H1 2018
  • Dormant Projects, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018

영문목차

Summary:

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) pipeline Target constitutes close to 31 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes. The latest report GTPase KRas - Pipeline Review, H1 2018, outlays comprehensive information on the GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - KRAS is a GTPase encoded by the KRAS gene. It plays an important role in the regulation of cell proliferation, promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner.

The molecules developed by companies in Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 14 and 10 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Metabolic Disorders and Ophthalmology which include indications Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Breast Cancer, Lung Cancer, Solid Tumor, Actinic (Solar) Keratosis, Basal Cell Carcinoma (Basal Cell Epithelioma), Colon Cancer, Corneal Neovascularization, Diabetic Retinopathy, Glioblastoma Multiforme (GBM), Macular Degeneration, Melanoma, Osteosarcoma, Prostate Cancer, Small-Cell Lung Cancer and Squamous Cell Carcinoma.

Furthermore, this report also reviews key players involved in GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)
  • The report reviews GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Overview
    • GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Companies Involved in Therapeutics Development
    • AstraZeneca Plc
    • Aurigene Discovery Technologies Ltd
    • Boehringer Ingelheim GmbH
    • Codiak BioSciences Inc
    • Cotinga Pharmaceuticals Inc
    • InteRNA Technologies BV
    • Kyowa Hakko Kirin Co Ltd
    • Mirati Therapeutics Inc
    • Moderna Therapeutics Inc
    • Nuevolution AB
    • PeptiDream Inc
    • Takeda Pharmaceutical Co Ltd
    • Tosk Inc
    • Warp Drive Bio Inc
  • GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Drug Profiles
    • ARS-853 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-4785 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • COTI-219 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HD-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INT-1B3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KHK-KRAS - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Krasin-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KRpep-2d - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MM-41 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit KRAS for Pancreatic Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mRNA-5671 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MRTX-849 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotide to Inhibit KRAS for Lung Cancer and Colon Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotides to Inhibit KRAS for Pancreatic Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SBT-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SBT-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SBT-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SBT-300 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit K-RAS for Non-Small Cell Lung Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit KRAS for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit KRAS for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit KRAS for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules 1 to Inhibit K-Ras for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules 3 to Inhibit K-Ras for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit K Ras for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit K-Ras for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit KRAS for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit KRAS2B for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SML-8731 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit KRAS for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target K-RAS for Lung Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Dormant Products
  • GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Product Development Milestones
    • Featured News & Press Releases
      • May 03, 2018: Moderna and Merck Expand mRNA Cancer Vaccines Collaboration
      • Apr 18, 2018: InteRNA Demonstrates Preclinical Proof-of-Concept for Lead microRNA Candidate INT-1B3 in a Range of Cancer Models at 2018 AACR Annual Meeting
      • Nov 13, 2017: Mirati Therapeutics Announces Advancement Of First-In-Class Opportunities With Sitravatinib And KRAS Inhibitor Programs
      • Dec 16, 2016: Ionis Earns $28 Million from AstraZeneca for a New Drug to Treat Cancer
      • Oct 11, 2016: Critical Outcome Technologies Announces Next Clinical Candidate, COTI-219, Targeting KRAS
      • Aug 29, 2016: FDA Grants Orphan Drug Designation to SBT-100 for Pancreatic Cancer
      • Jul 29, 2014: Researchers Identify Irreversible Inhibitor for KRAS Gene Mutation
      • May 08, 2013: Sentinel Oncology Achieves Milestone In Horizon Discovery Agreement
      • Jan 03, 2013: Kyowa Hakko Kirin Selects Second DsiRNA Therapeutic Candidate For Development, Triggering $5m Milestone Payment To Dicerna Pharma
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research